Eurofarma launches Synapsis, Startup acceleration program in partnership with Endeavor
Published in: November 7, 2017
and updated in: November 4, 2021
Listen to the text
Stop the audio
São Paulo, October 2017 – Eurofarma, a multinational pharmaceutical company with 100% Brazilian capital, announces today the launch of the Eurofarma Synapsis platform, which together with Endeavor will select 12 startups aimed at innovation in the health area to receive support and accelerate growth. Entries can be made until February 9, 2018 on the Eurofarma Synapsis page, and the companies selected to present their projects will be announced on the 23rd of the same month. On March 8, a bank made up of executives from Eurofarma and Endeavor will select the 12 companies that will be part of the program.
The new innovation platform is looking for scale-ups, startups that are already operational and growing. Innovations should focus on the following areas:
• Relationship with interest groups (doctors/patients/pharmacists/distributors/hospitals)
• Generating added value in services and innovating the way we relate to our stakeholders
• Gaining efficiencies in key processes
• Research & Development (processes related to the development of new products)
• Industrial Operations and Administrative(improving the efficiency and productivity of all logistics processes)
• Sustainability
• Look for more sustainable alternatives in the health chain (focus: waste, energy efficiency, water and emissions)
• Market Intelligence
• Optimization of existing tools, big data and use of other technologies to offer new services and add value to products
• People Management
• New management models for engaging, attracting and retaining talent.
The selected companies will have access to mentoring with the Endeavor network and access to entrepreneurs at a similar growth stage. In addition, startups will be able to leverage their business by making contact with information and trends in the healthcare industry - broadly audited, coaching in support areas such as Marketing, Sales and Logistics, in addition to access to Eurofarma's network of relationships that includes more than 4 thousand suppliers, more than 1,500 active customers (B2B) and maintains 600 thousand more medical contacts per month, covering all specialties.
The decision to invest in scale-ups is aligned with Eurofarma's objectives and with its growth strategy strongly supported by innovation. For Maria Del Pilar Muñoz, vice-president of Sustainability and New Business, Synapsis represents an important advance in the innovation strategy. "Eurofarma emerged from a dream and 45 years ago it was also a startup. Today, we are inaugurating a new stage in partnership with companies that, like us, wish to grow. And our proposal is to speed up this process", he says.
Endeavor, a partner in this venture, will be in charge of contacting the startups and assisting in the screening process. The companies will be evaluated by a multidisciplinary team, which in addition to looking at the product or solution, will analyze the profile of the entrepreneur and their compatibility with Eurofarma. "Continuing to grow and taking a company to a new level is a huge challenge. It demands talents, capital and an entrepreneur with a really great, resilient and able-bodied dream. It is at this turning point that Synapsis will help - by making good connections so that entrepreneurs can make better decisions and learn from those who have already made theirs", says Igor Piquet, Director of Endeavor Entrepreneurship Support.
"Eurofarma invests 6% of its R&D revenue and is expected to reach 10% in the coming years. The launch of new products and international expansion will continue to drive our growth. At the same time, innovation must permeate all areas and processes of the company, so that it becomes even more avant-garde and competitive. It is in this context that Eurofarma Synapsis has emerged. In the medium term, the open innovation platform could receive 5% of the company's net profit", concludes Pilar.
Service:
Enrollment Date: from November 08, 2017 to February 09, 2018
Site: endeavor.org.br/scaleup/eurofarma-synapsis
Who can participate: entrepreneurs in the health areas that already have an operating company with a potential for growth
Selected companies: February 23, 2018
Internal selection bank with pitch presentation: March 08, 2018. Selection of the 12 companies that will be part of the program by a bank formed by Eurofarma executives and from the Endeavor network
About Endeavor
Endeavor is a global, non-profit organization that fosters entrepreneurship.
In Brazil, since 2000, it exists to multiply the power of transformation of the Brazilian entrepreneur. To this end, it selects and supports entrepreneurs with the greatest potential for growth and impact, shares their stories and learning, and promotes studies to guide public policies aimed at improving the business environment in Brazil. In 2016 alone, it directly supported entrepreneurs who, together, generated almost R$ 4 billion in revenue, and inspired 7 million people through its Portal.
About the Eurofarma Group
First pharmaceutical multinational with 100% Brazilian capital, Eurofarma has 45 years of existence, 6,500 employees and is present with its own operations in 20 Latin American countries.
With 12 manufacturing plants in the region, the company has more than 280 products in its portfolio. In 2016, it produced more than 290 million units and reached revenues of R$ 3.3 billion, 15.7% higher than the previous one. The Group invests approximately 5.5% of its net sales in Research & Development and maintains more than 175 projects in its pipeline.
About Eurofarma Brazil
Considered one of the best companies to work, according to Great Place to Work, it is also considered the most sustainable pharmaceutical in the country by Guia Exame de Sustentabilidade. With operations in the main pharmaceutical segments, namely Prescription Medical, Generic, Hospital, Oncology, Veterinary, Bids and Services to Third Parties, Eurofarma holds the largest force of medical advertisement in Brazil. In all, it has more than 2,000 representatives who make about 450,000 medical contacts/month. It is among the four largest pharmacies in the country and is the second most prescribed one by doctors.
For more information, visit www.eurofarma.com.br
Press Release
Eurofarma
G&A Public Relations - Clareane Moraes | +55 (11) 3065-3045 | clareane@gaspar.com.br
Guilherme Gaspar | +55 (11) 3065-3049 | guilherme@gaspar.com.br
Endeavor – Barbara Freiris | +55 (11) 4504-2477| barbara.freiris@endeavor.org.br
The new innovation platform is looking for scale-ups, startups that are already operational and growing. Innovations should focus on the following areas:
• Relationship with interest groups (doctors/patients/pharmacists/distributors/hospitals)
• Generating added value in services and innovating the way we relate to our stakeholders
• Gaining efficiencies in key processes
• Research & Development (processes related to the development of new products)
• Industrial Operations and Administrative(improving the efficiency and productivity of all logistics processes)
• Sustainability
• Look for more sustainable alternatives in the health chain (focus: waste, energy efficiency, water and emissions)
• Market Intelligence
• Optimization of existing tools, big data and use of other technologies to offer new services and add value to products
• People Management
• New management models for engaging, attracting and retaining talent.
The selected companies will have access to mentoring with the Endeavor network and access to entrepreneurs at a similar growth stage. In addition, startups will be able to leverage their business by making contact with information and trends in the healthcare industry - broadly audited, coaching in support areas such as Marketing, Sales and Logistics, in addition to access to Eurofarma's network of relationships that includes more than 4 thousand suppliers, more than 1,500 active customers (B2B) and maintains 600 thousand more medical contacts per month, covering all specialties.
The decision to invest in scale-ups is aligned with Eurofarma's objectives and with its growth strategy strongly supported by innovation. For Maria Del Pilar Muñoz, vice-president of Sustainability and New Business, Synapsis represents an important advance in the innovation strategy. "Eurofarma emerged from a dream and 45 years ago it was also a startup. Today, we are inaugurating a new stage in partnership with companies that, like us, wish to grow. And our proposal is to speed up this process", he says.
Endeavor, a partner in this venture, will be in charge of contacting the startups and assisting in the screening process. The companies will be evaluated by a multidisciplinary team, which in addition to looking at the product or solution, will analyze the profile of the entrepreneur and their compatibility with Eurofarma. "Continuing to grow and taking a company to a new level is a huge challenge. It demands talents, capital and an entrepreneur with a really great, resilient and able-bodied dream. It is at this turning point that Synapsis will help - by making good connections so that entrepreneurs can make better decisions and learn from those who have already made theirs", says Igor Piquet, Director of Endeavor Entrepreneurship Support.
"Eurofarma invests 6% of its R&D revenue and is expected to reach 10% in the coming years. The launch of new products and international expansion will continue to drive our growth. At the same time, innovation must permeate all areas and processes of the company, so that it becomes even more avant-garde and competitive. It is in this context that Eurofarma Synapsis has emerged. In the medium term, the open innovation platform could receive 5% of the company's net profit", concludes Pilar.
Service:
Enrollment Date: from November 08, 2017 to February 09, 2018
Site: endeavor.org.br/scaleup/eurofarma-synapsis
Who can participate: entrepreneurs in the health areas that already have an operating company with a potential for growth
Selected companies: February 23, 2018
Internal selection bank with pitch presentation: March 08, 2018. Selection of the 12 companies that will be part of the program by a bank formed by Eurofarma executives and from the Endeavor network
About Endeavor
Endeavor is a global, non-profit organization that fosters entrepreneurship.
In Brazil, since 2000, it exists to multiply the power of transformation of the Brazilian entrepreneur. To this end, it selects and supports entrepreneurs with the greatest potential for growth and impact, shares their stories and learning, and promotes studies to guide public policies aimed at improving the business environment in Brazil. In 2016 alone, it directly supported entrepreneurs who, together, generated almost R$ 4 billion in revenue, and inspired 7 million people through its Portal.
About the Eurofarma Group
First pharmaceutical multinational with 100% Brazilian capital, Eurofarma has 45 years of existence, 6,500 employees and is present with its own operations in 20 Latin American countries.
With 12 manufacturing plants in the region, the company has more than 280 products in its portfolio. In 2016, it produced more than 290 million units and reached revenues of R$ 3.3 billion, 15.7% higher than the previous one. The Group invests approximately 5.5% of its net sales in Research & Development and maintains more than 175 projects in its pipeline.
About Eurofarma Brazil
Considered one of the best companies to work, according to Great Place to Work, it is also considered the most sustainable pharmaceutical in the country by Guia Exame de Sustentabilidade. With operations in the main pharmaceutical segments, namely Prescription Medical, Generic, Hospital, Oncology, Veterinary, Bids and Services to Third Parties, Eurofarma holds the largest force of medical advertisement in Brazil. In all, it has more than 2,000 representatives who make about 450,000 medical contacts/month. It is among the four largest pharmacies in the country and is the second most prescribed one by doctors.
For more information, visit www.eurofarma.com.br
Press Release
Eurofarma
G&A Public Relations - Clareane Moraes | +55 (11) 3065-3045 | clareane@gaspar.com.br
Guilherme Gaspar | +55 (11) 3065-3049 | guilherme@gaspar.com.br
Endeavor – Barbara Freiris | +55 (11) 4504-2477| barbara.freiris@endeavor.org.br